Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD+ Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts

Bruno Paiva,Irene Manrique,Nicola Giuliani,Michele Cavo,Christine Rojas,Weijun Fu,María-Victoria Mateos,Meletios A Dimopoulos,Alexander Vorog,Cong Li,Bingxia Wang,Richard J Labotka,Ajeeta B Dash

doi:10.1182/blood-2020-136105

Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD+ Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts

Bruno Paiva, Irene Manrique + Show 11 more

Open Access

https://doi.org/10.1182/blood-2020-136105

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2020
Citations: 1

Affiliation: Takeda (United States), Millennium Engineering and Integration (United States), Navarre Institute of Health Research, Clinica Universidad de Navarra, Centro de Investigación del Cáncer, University of Valparaíso, University of Chile, National and Kapodistrian University of Athens, Shanghai Changzheng Hospital, University of Parma

#Measurable Residual Disease #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD+ Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts

Full Text